Obese men are at increased risk for erectile dysfunction, likely caused by atherosclerosis-related hypertension and cardiovascular disease, as well as hormonal changes associated with obesity.
Palatin Technologies, Inc. (NYSE Amex: PTN) announced the completion of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD). The results demonstrate that with subcutaneous administration consistent therapeutic blood plasma levels can be obtained without blood pressure side effects.
UroToday.com – A UCLA single-institution study in the online edition of the Journal of Urology reports on the use of erectile aid (EA) following treatment for localized prostate cancer (CaP). Participants with a diagnosis of CaP were prospectively recruited between 1999 and 2003. Clinical and pathological data was abstracted and HRQOL (Health Related Quality of Life) outcomes were prospectively abstracted at baseline and 1, 2, 4, 8, 12, 18, 24, 30, 36, 42 and 48 months.
UroToday.com – Most recently, health-related quality-of-life (HRQOL) after definitive local therapy for prostate cancer has been argued in the patient group with an oncological risk category.
Sciele Pharma Inc., a Shionogi Company, and Plethora Solutions Holdings PLC (”Plethora” – AIM:PLE), announced that a second and final Phase III double-blind, placebo-controlled study of PSD502 for the treatment of premature ejaculation (’PE’) has met all co-primary endpoints of Intra-vaginal Ejaculation Latency Time (’IELT’), Index of Premature Ejaculation (’IPE,’ Ejaculatory Control, Sexual Satisfaction and Distress domains).
UroToday.com – Men with benign prostatic hyperplasia (BPH) often suffer from lower urinary tract symptoms (LUTS; BPH-LUTS) such as urinary frequency, urgency, intermittency, nocturia, straining, incomplete emptying, or weak urinary stream. BPH-LUTS and erectile dysfunction (ED), both highly prevalent conditions in aging men, are frequently associated in the same men, may have common pathophysiological mechanisms, and contribute negatively to quality of life.
Two Indiana University studies conducted among nationally representative samples of adult American men and women show that vibrator use during sexual interactions is common, with use being reported by approximately 53 percent of women and 45 percent of men ages 18 to 60. Not only is vibrator use common, but the two studies also show that vibrator use is associated with more positive sexual function and being more proactive in caring for one’s sexual health.
Couples’ treatment for sexual problems and other innovative approaches to improving sexual health for men and women are on the agenda of sexual medicine experts.
A long-term study by researchers at UCLA’s Jonsson Comprehensive Cancer Center found that the three most common treatments for localized prostate cancer had significant impacts on patients’ quality of life, a finding that could help guide doctors and patients in making treatment decisions.